EW - Edwards Lifesciences Corporation

Edwards Lifesciences Comments on TAVR National Coverage Decision

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):“Edwards is pleased that this updated policy represents an important step toward improving and expanding patient access to TAVR while reinforcing the value of a multidisciplinary Heart Team. Aortic stenosis is a serious, pro.

Sep 10, 2026 01:49 PM • businesswire.com

Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Sep 07, 2026 11:32 AM • prnewswire.com

Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive officer, is scheduled to present at 10:00 a.m. ET. Doretta Mistras, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessibl.

Sep 02, 2026 12:15 PM • businesswire.com

128,603 Shares in Edwards Lifesciences Corporation $EW Acquired by Beacon Pointe Advisors LLC

Beacon Pointe Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 128,603 shares of the medical research company's stock, valued at approximately $11,632,000. A number of

Aug 29, 2026 12:11 AM • defenseworld.net

Is EW Overvalued? DCF Says Worth $53

On August 26, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has seen a price performance of +12.4% over the past year

Aug 26, 2026 03:22 AM • gurufocus.com

Bank of Nova Scotia Takes Position in Edwards Lifesciences Corporation $EW

Bank of Nova Scotia bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 60,417 shares of the medical research company's stock, valued at approximately $5,465,000. Several other hedge funds also recently made

Aug 25, 2026 11:54 PM • defenseworld.net

37,702 Shares in Edwards Lifesciences Corporation $EW Bought by EP Wealth Advisors LLC

EP Wealth Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 37,702 shares of the medical research company's stock, valued at approximately $3,410,000. Other institutional investors and hedge

Aug 23, 2026 12:30 AM • defenseworld.net

B. Metzler seel. Sohn & Co. AG Buys Shares of 41,753 Edwards Lifesciences Corporation $EW

B. Metzler seel. Sohn and Co. AG acquired a new position in Edwards Lifesciences Corporation (NYSE: EW) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 41,753 shares of the medical research company's stock, valued at approximately $3,777,000. Several other hedge

Aug 21, 2026 11:57 PM • defenseworld.net

Allworth Financial LP Takes Position in Edwards Lifesciences Corporation $EW

Allworth Financial LP bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 16,600 shares of the medical research company's stock, valued at approximately $1,502,000. A number of other hedge funds have also

Aug 21, 2026 11:11 PM • defenseworld.net

Should You Hold Edwards Lifesciences Stock in Your Portfolio?

EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.

Aug 20, 2026 07:46 AM • zacks.com

BlackRock Inc. Acquires New Stake in Edwards Lifesciences Corporation $EW

BlackRock Inc. bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 58,789,433 shares of the medical research company's stock, valued at approximately $5,318,092,000. BlackRock Inc. owned approximately 10.21% of Edwards Lifesciences at the end

Aug 18, 2026 11:57 PM • defenseworld.net

Baxter Bros Inc. Invests $3.54 Million in Edwards Lifesciences Corporation $EW

Baxter Bros Inc. purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE: EW) during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 39,184 shares of the medical research company's stock, valued at approximately $3,545,000. A number of other large investors have

Aug 17, 2026 12:33 AM • defenseworld.net

Bank Hapoalim BM Makes New $1.78 Million Investment in Edwards Lifesciences Corporation $EW

Bank Hapoalim BM purchased a new stake in Edwards Lifesciences Corporation (NYSE: EW) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 19,640 shares of the medical research company's stock, valued at approximately $1,777,000. A number of other large investors

Aug 16, 2026 12:27 AM • defenseworld.net

Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?

Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.

Aug 14, 2026 08:41 AM • zacks.com

Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation

Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.

Aug 13, 2026 05:55 AM • zacks.com

EW DCF Analysis: Intrinsic Value $53 vs Price $90

On August 05, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown mixed price performance recently. The stock has

Aug 05, 2026 03:26 AM • gurufocus.com

Edwards Lifesciences Corporation $EW Stock Holdings Lessened by Glenmede Trust Co. NA

Glenmede Trust Co. NA trimmed its stake in shares of Edwards Lifesciences Corporation (NYSE: EW) by 4.0% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 167,483 shares of the medical research company's stock after selling 6,923 shares

Aug 03, 2026 12:41 AM • defenseworld.net

Is the Options Market Predicting a Spike in Edwards Lifesciences Stock?

Investors need to pay close attention to EW stock based on the movements in the options market lately.

Jul 30, 2026 07:36 AM • zacks.com

Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says

Edwards Lifesciences Corp. (NYSE:EW) stock rose Friday after the medical device maker reported second-quarter results that topped Wall Street estimates and raised the low end of its full-year revenue guidance.

Jul 24, 2026 07:48 AM • benzinga.com

Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises

EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.

Jul 24, 2026 05:56 AM • zacks.com

Edwards Lifesciences upgraded to Buy from Neutral at UBS

$110.00 (was $83.04)

UBS

Jul 28, 2026 06:35 AM • TheFly

Edwards Lifesciences price target raised to $101 from $100 at Piper Sandler

$101.00 (was $83.82)

Piper Sandler

Jul 24, 2026 07:20 AM • TheFly

Edwards Lifesciences upgraded to Outperform from Market Perform at Leerink

$101.00 (was $83.82)

Mike Kratky · Leerink Partners

Jul 24, 2026 06:26 AM • TheFly

Edwards Lifesciences price target raised to $95 from $90 at Truist

$95.00 (was $86.78)

Richard Newitter · Truist Financial

Jul 16, 2026 10:04 AM • TheFly

Edwards Lifesciences price target raised to $110 from $100 at RBC Capital

$110.00 (was $92.03)

RBC Capital

Jul 13, 2026 09:13 AM • TheFly

Edwards Lifesciences price target raised to $100 from $93 at Evercore ISI

$100.00 (was $93.11)

Evercore ISI

Jul 06, 2026 08:43 AM • TheFly

Edwards Lifesciences price target raised to $110 from $100 at BTIG

$110.00 (was $91.18)

Marie Thibault · BTIG

Jun 30, 2026 07:25 AM • TheFly

Edwards Lifesciences price target raised to $110 from $104 at Barclays

$110.00 (was $84.15)

Barclays

Apr 27, 2026 05:48 AM • TheFly

Edwards Lifesciences price target raised to $90 from $89 at Truist

$90.00 (was $83.15)

Truist Financial

Apr 24, 2026 09:29 AM • TheFly

Edwards Lifesciences price target raised to $93 from $92 at Evercore ISI

$93.00 (was $83.12)

Vijay Kumar · Evercore ISI

Apr 24, 2026 08:09 AM • TheFly

Edwards Lifesciences price target raised to $100 from $98 at BTIG

$100.00 (was $79.72)

BTIG

Apr 24, 2026 07:27 AM • TheFly

Edwards Lifesciences price target lowered to $85 from $87 at Canaccord

$85.00 (was $79.72)

William Plovanic · Canaccord Genuity

Apr 24, 2026 06:59 AM • TheFly

Edwards Lifesciences price target lowered to $95 from $100 at Mizuho

$95.00 (was $77.28)

Mizuho Securities

Apr 13, 2026 10:38 AM • TheFly

Edwards Lifesciences price target lowered to $89 from $92 at Truist

$89.00 (was $76.85)

Richard Newitter · Truist Financial

Feb 11, 2026 08:30 AM • TheFly

Edwards Lifesciences price target lowered to $95 from $108 at Goldman Sachs

$95.00 (was $77.05)

David Roman · Goldman Sachs

Feb 11, 2026 06:54 AM • TheFly

Edwards Lifesciences price target raised to $100 from $98 at Piper Sandler

$100.00 (was $77.05)

Piper Sandler

Feb 11, 2026 06:46 AM • TheFly

Edwards Lifesciences price target lowered to $94 from $95 at UBS

$94.00 (was $81.62)

Danielle Antalffy · UBS

Feb 04, 2026 09:15 AM • TheFly

Edwards Lifesciences price target raised to $110 from $105 at Stifel

$110.00 (was $84.35)

Stifel Nicolaus

Jan 20, 2026 07:27 AM • TheFly

Edwards Lifesciences price target raised to $98 from $95 at Piper Sandler

$98.00 (was $84.35)

Piper Sandler

Jan 20, 2026 06:45 AM • TheFly

Edwards Lifesciences price target raised to $95 from $92 at UBS

$95.00 (was $83.58)

Danielle Antalffy · UBS

Jan 12, 2026 09:10 AM • TheFly